http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
Aeterna Zentaris (AEZS) Outlines Progress on Development Pipeline Programs and Provides Corporate Update
-
Aeterna Zentaris (AEZS) Outlines Progress on Development Pipeline Programs and Provides Corporate Update
-
Aeterna Zentaris Outlines Progress on Development Pipeline Programs and Provides Corporate Update
-
Aeterna Zentaris to Participate in the Virtual Investor Summer Spotlight Series
-
Aeterna Zentaris Announces Results of Virtual 2023 Meeting of Shareholders
-
Aeterna Zentaris Announces Virtual 2023 Meeting of Shareholders
-
Aeterna Zentaris Reports First Quarter 2023 Financial Results
-
Aeterna Zentaris Provides Update on Macrilen® (Macimorelin), Reiterates Advancement of Pediatric DETECT Trial
-
Aeterna Zentaris Reports Fourth Quarter and Full Year 2022 Financial Results
-
Aeterna Zentaris (AEZS) Announces Pharmanovia to Market GHRYVELIN in the European Economic Area and UK as Diagnostic Test for GHD
-
Pharmanovia to Market GHRYVELIN™ (Macimorelin) in the European Economic Area (EEA) and UK as Diagnostic Test for Growth Hormone Deficiency (GHD)
-
Aeterna Zentaris (AEZS) Provides Business Update and Outlines Key Upcoming Milestones
-
Aeterna Zentaris Provides Business Update and Outlines Key Upcoming Milestones
-
JTC Team to Host the Virtual Investor 2023 Companies to Watch Event on January 17th, 18th, and 19th
-
Aeterna Zentaris to Present at the Virtual Investor 2023 Companies to Watch Event
-
Aeterna Zentaris Reports Third Quarter 2022 Financial Results
-
Aeterna Zentaris Reports Third Quarter 2022 Financial Results
-
Aeterna Zentaris (AEZS) to Regain Full Rights to Macrilen in US and Canada
-
Aeterna Zentaris Set to Regain Full Rights to Macrilen™ (Macimorelin) in U.S. and Canada from Novo Nordisk
-
Aeterna Zentaris Set to Regain Full Rights to Macrilen™ (Macimorelin) in U.S. and Canada from Novo Nordisk
-
Aeterna Zentaris Reports Second Quarter 2022 Financial Results and Recent Highlights
-
Aeterna Zentaris Reports Second Quarter 2022 Financial Results and Recent Highlights
-
Aeterna Zentaris (AEZS) Sets July 21st as Date of Share Consolidation
-
Aeterna Zentaris Announces Effective Date of Share Consolidation
-
Aeterna Zentaris Announces Effective Date of Share Consolidation
-
Aeterna Zentaris (AEZS) Shareholders Approve 1:25 Share Consolidation
-
Aeterna Zentaris Announces Shareholder Approval of Share Consolidation
-
Aeterna Zentaris Announces Shareholder Approval of Share Consolidation
-
Aeterna Zentaris Announces Further Adjournment of Shareholder Meeting
-
Aeterna Zentaris Announces Further Adjournment of Shareholder Meeting
-
Aeterna Zentaris Announces Results of Annual Meeting of Shareholders
-
Aeterna Zentaris Announces Results of Annual Meeting of Shareholders
-
Aeterna Zentaris Achieves Proof-of-Concept for the Treatment of NMOSD with AIM Biologicals Program
-
Aeterna Zentaris Achieves Proof-of-Concept for the Treatment of NMOSD with AIM Biologicals Program
-
Aeterna Zentaris to Present at the JMP Securities Life Sciences Conference
-
Aeterna Zentaris to Present at the JMP Securities Life Sciences Conference
-
Aeterna Zentaris’ Licensing Partner, Consilient Health Announces European Launch of Ghryvelin™ (macimorelin) for Diagnosing Adult Growth Hormone Deficiency
-
Aeterna Zentaris’ Licensing Partner, Consilient Health Announces European Launch of Ghryvelin™ (macimorelin) for Diagnosing Adult Growth Hormone Deficiency
-
Aeterna Zentaris to Present at the H.C. Wainwright Global Investment Conference
-
Aeterna Zentaris to Present at the H.C. Wainwright Global Investment Conference
-
Aeterna Zentaris Announces Virtual 2022 Meeting of Shareholders and Urges Shareholders to Vote in Favor of the Proposed Share Consolidation
-
Aeterna Zentaris Announces Virtual 2022 Meeting of Shareholders and Urges Shareholders to Vote in Favor of the Proposed Share Consolidation
-
Aeterna Zentaris (AEZS) Provides Update on Positive Pre-Clinical Results from AIM Biologicals Development Program for the Potential Treatment of Parkinson’s Disease
-
Update on Positive Pre-Clinical Results from AIM Biologicals Development Program for the Potential Treatment of Parkinson’s Disease
-
Update on Positive Pre-Clinical Results from AIM Biologicals Development Program for the Potential Treatment of Parkinson’s Disease
-
Aeterna Zentaris (AEZS) Reports Q1 Net Loss of $2.6M, Provides Business Outlook
-
Aeterna Zentaris Reports First Quarter 2022 Financial Results and Provides Business Outlook
-
Aeterna Zentaris Reports First Quarter 2022 Financial Results and Provides Business Outlook
-
Aeterna Zentaris Abstract Accepted for Presentation at IMMUNOLOGY2022™, the Annual Event of the American Association of Immunologists
-
Aeterna Zentaris Abstract Accepted for Presentation at IMMUNOLOGY2022™, the Annual Event of the American Association of Immunologists
